[ { "@graph" : [ { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#pubinfo" } ] } ], "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#Head" }, { "@graph" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_1040", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association", "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_1040" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "https://identifiers.org/drugbank:DB06769" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "bendamustine hydrochloride injection is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia cll efficacy relative to first line therapies other than chlorambucil has not been established 1 1 indolent b cell non hodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen 1 2 bendamustine hydrochloride injection is indicated for the treatment of patients with chronic lymphocytic leukemia efficacy relative to first line therapies other than chlorambucil has not been established bendamustine hydrochloride injection is indicated for the treatment of patients with indolent b cell non hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen" } ], "https://w3id.org/biolink/vocab/association_type" : [ { "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" } ], "https://w3id.org/biolink/vocab/provided_by" : [ { "@id" : "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "https://schema.org/TreatmentIndication" } ] }, { "@id" : "https://identifiers.org/drugbank:DB06769", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] } ], "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ] } ], "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs", "http://purl.org/dc/terms/created" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2021-06-30T09:01:14.488+02:00" } ], "http://purl.org/dc/terms/creator" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ { "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ { "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs" } ] }, { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "GqyRk24dx5beTXKfGlW3ci8maICZ8+4mY5osqfCLIb+5MEmMrwpGvFLHSbhiNmgENgmI8mMWHO1YTwHmQu68KG4hX07WINWpInFxqiy8eYhT1yhGn0Sfdzl+ZidIubsvzNjVyTuA6Fh4aspkVlIqW88Tcwfqk6vfusERm6x9Kx0=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs" } ] } ], "@id" : "http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#pubinfo" } ]